{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T02:59:59Z","timestamp":1780887599699,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018063","name":"Bowel Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000872","name":"Pelican Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000872","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Locally recurrent rectal cancer (LRRC) is an emerging area for research; however, it represents significant challenges as a relatively rare form of advanced pelvic malignancy, from both a recruitment and study setup and delivery perspective. To date, there have been relatively few published trials in this setting. High-quality, multi-centre, prospective studies could offer helpful insights regarding the challenges associated with delivering studies in rare disease settings such as LRRC, and how to effectively address them.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Locally Recurrent Rectal Cancer\u2014Quality of Life (LRRC-QoL) study is an international, multi-centre, mixed-methods study of health-related quality of life (HrQoL) in LRRC. The International Surgical Trials Toolkit was utilised as a guideline in navigating site setup processes and to describe the challenges encountered during this study. A modified Quintet Recruitment Intervention (QRI) was used as a framework to identify recruitment challenges and drive improvements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 227 patients were recruited to the LRRC-QoL study across 14 countries. Significant challenges were encountered during site setup, including issues related to legal agreements which were further complicated by Brexit, expenses related to translation, and requirements for multiple ethical approvals. Delays during study setup and recruitment challenges occurred due to the COVID-19 pandemic. Several strategies were identified through the modified QRI with a positive impact on recruitment. Recruitment pathways were refined to a more streamlined, centralised approach, facilitated by verbal consent to contact. Recruitment rates also improved with the introduction of multiple options for participation, including traditional paper-based methods, online, and via telephone. Patient information leaflets were refined following patient and public involvement (PPI) work.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Several approaches identified during the LRRC-QoL study should be considered in the development of future studies and trials recruiting patients with LRRC. These include undertaking PPI during study development, identifying flexible recruitment strategies which complement sites\u2019 existing clinical processes, and partnering with existing collaborative networks.<\/jats:p>\n                    <jats:p>Study registration<\/jats:p>\n                    <jats:p>\n                      The LRRC-QoL study registration reference: ISRCTN13692671 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/doi.org\/10.1186\/ISRCTN13692671\" ext-link-type=\"uri\">https:\/\/doi.org\/10.1186\/ISRCTN13692671<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09264-0","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:05:51Z","timestamp":1777071951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges and strategies to improve recruitment in international, multi-centre research studies in locally recurrent rectal cancer: experience from the Locally Recurrent Rectal Cancer\u2014Quality of Life (LRRC-QoL) study"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1599-5701","authenticated-orcid":false,"given":"Niamh","family":"McKigney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Velikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deena P.","family":"Harji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"11","key":"9264_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/codi.12944","volume":"17","author":"DP Harji","year":"2015","unstructured":"Harji DP, Koh C, Solomon M, Velikova G, Sagar PM, Brown J. Development of a conceptual framework of health-related quality of life in locally recurrent rectal cancer. Colorectal Dis. 2015;17(11):954\u201364.","journal-title":"Colorectal Dis"},{"issue":"8","key":"9264_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1308\/rcsann.2022.0045","volume":"104","author":"DP Harji","year":"2022","unstructured":"Harji DP, Houston F, Cutforth I, Hawthornthwaite E, McKigney N, Sharpe A, et al. The impact of multidisciplinary team decision-making in locally advanced and recurrent rectal cancer. Ann R Coll Surg Engl. 2022;104(8):611\u20137.","journal-title":"Ann R Coll Surg Engl"},{"issue":"13","key":"9264_CR3","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1002\/bjs.11854","volume":"107","author":"Q Denost","year":"2020","unstructured":"Denost Q, Solomon M, Tuech J-J, Ghouti L, Cotte E, Panis Y, et al. International variation in managing locally advanced or recurrent rectal cancer: prospective benchmark analysis. Br J Surg. 2020;107(13):1846\u201354.","journal-title":"Br J Surg"},{"issue":"6","key":"9264_CR4","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.ejso.2020.02.031","volume":"46","author":"SJ O\u2019Shannassy","year":"2020","unstructured":"O\u2019Shannassy SJ, Brown KGM, Steffens D, Solomon MJ. Referral patterns and outcomes of a highly specialised pelvic exenteration multidisciplinary team meeting: a retrospective cohort study. Eur J Surg Oncol. 2020;46(6):1138\u201343.","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"9264_CR5","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1002\/bjs.11924","volume":"107","author":"C PelvEx","year":"2020","unstructured":"PelvEx C. The global cost of pelvic exenteration: in-hospital perioperative costs. BJS (British Journal of Surgery). 2020;107(11):e470\u20131.","journal-title":"BJS (British Journal of Surgery)"},{"issue":"6","key":"9264_CR6","first-page":"650","volume":"105","author":"TP Collaborative","year":"2018","unstructured":"Collaborative TP. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. 2018;105(6):650\u20137.","journal-title":"Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer"},{"key":"9264_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002670","author":"AK Kalpakidou","year":"2021","unstructured":"Kalpakidou AK, Todd C, Omar RZ, Keeley V, Griffiths J, Spencer K, et al. Study recruitment factors in advanced cancer: the prognosis in palliative care study II (PiPS2) - a multicentre, prospective, observational cohort project. BMJ Support Palliat Care. 2021. https:\/\/doi.org\/10.1136\/bmjspcare-2020-002670.","journal-title":"BMJ Support Palliat Care"},{"issue":"2","key":"9264_CR8","first-page":"e49","volume":"21","author":"A Bertaut","year":"2022","unstructured":"Bertaut A, Touchefeu Y, Blanc J, Bouch\u00e9 O, Fran\u00e7ois E, Conroy T, et al. Health-related quality of life analysis in metastatic colorectal cancer patients treated by second-line chemotherapy, associated with either cetuximab or bevacizumab: the PRODIGE 18 randomized phase II study. Clin Colorectal Cancer. 2022;21(2):e49\u201361.","journal-title":"Clin Colorectal Cancer"},{"issue":"7","key":"9264_CR9","doi-asserted-by":"publisher","first-page":"O223","DOI":"10.1111\/codi.12551","volume":"16","author":"HV Thaysen","year":"2014","unstructured":"Thaysen HV, Jess P, Rasmussen PC, Nielsen MB, Laurberg S. Health-related quality of life after surgery for advanced and recurrent rectal cancer: a nationwide prospective study. Colorectal Dis. 2014;16(7):O223\u201333.","journal-title":"Colorectal Dis"},{"issue":"11","key":"9264_CR10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/ans.13419","volume":"87","author":"I Choy","year":"2017","unstructured":"Choy I, Young JM, Badgery-Parker T, Masya LM, Shepherd HL, Koh C, et al. Baseline quality of life predicts pelvic exenteration outcome. ANZ J Surg. 2017;87(11):935\u20139.","journal-title":"ANZ J Surg"},{"issue":"10","key":"9264_CR11","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/pon.3520","volume":"23","author":"S Jennings","year":"2014","unstructured":"Jennings S, Philip EJ, Nelson C, Schuler T, Starr T, Jandorf L, et al. Barriers to recruitment in psycho-oncology: unique challenges in conducting research focusing on sexual health in female survivorship. Psychooncology. 2014;23(10):1192\u20135.","journal-title":"Psychooncology"},{"issue":"1","key":"9264_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2645-0","volume":"19","author":"RA Crow","year":"2018","unstructured":"Crow RA, Hart KA, McDermott MP, Tawil R, Martens WB, Herr BE, et al. A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial. Trials. 2018;19(1):291.","journal-title":"Trials"},{"issue":"1\u20132","key":"9264_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2011.10.004","volume":"313","author":"G Minisman","year":"2012","unstructured":"Minisman G, Bhanushali M, Conwit R, Wolfe GI, Aban I, Kaminski HJ, et al. Implementing clinical trials on an international platform: challenges and perspectives. J Neurol Sci. 2012;313(1\u20132):1\u20136.","journal-title":"J Neurol Sci"},{"key":"9264_CR14","unstructured":"(CTRU) UoLCTRU. International Surgical Trials Toolkit 2021 [Available from: https:\/\/internationaltrialstoolkit.co.uk\/about-us\/."},{"key":"9264_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1391-4","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Rooshenas L, Jepson M, Elliott D, Wade J, Avery K, et al. Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the quintet recruitment intervention (QRI). Trials. 2016. https:\/\/doi.org\/10.1186\/s13063-016-1391-4.","journal-title":"Trials"},{"key":"9264_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jclinepi.2018.10.004","volume":"106","author":"L Rooshenas","year":"2019","unstructured":"Rooshenas L, Scott LJ, Blazeby JM, Rogers CA, Tilling KM, Husbands S, et al. The quintet recruitment intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. J Clin Epidemiol. 2019;106:108\u201320.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"9264_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13063-017-2413-6","volume":"19","author":"C Wilson","year":"2018","unstructured":"Wilson C, Rooshenas L, Paramasivan S, Elliott D, Jepson M, Strong S, et al. Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (screened, eligible, approached, randomised) framework. Trials. 2018;19(1):50.","journal-title":"Trials"},{"key":"9264_CR18","unstructured":"Department of Health. Attributing the costs of health and social care research (AcoRD guidance). GOV. UK.\u00a02012."},{"key":"9264_CR19","unstructured":"(IRAS) IRAS. Site specific information myresearchproject.org.uk IRAS; 2021. [Available from: https:\/\/www.myresearchproject.org.uk\/help\/hlpsitespecific.aspx#PIC."},{"key":"9264_CR20","unstructured":"(CTRU) UoLCTRU. International Surgical Trials Toolkit: contracts 2021 [Available from: https:\/\/internationaltrialstoolkit.co.uk\/considerations\/contracts\/."},{"key":"9264_CR21","unstructured":"Council Directive 65\/65\/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products, OJ. 1965. L 22, p. 369."},{"key":"9264_CR22","unstructured":"Regulation (EU) 2016\/679 of the European Parliament and of the Council on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation).\u00a02016."},{"key":"9264_CR23","unstructured":"Data Protection Act 2018, c. 12. Available at: https:\/\/www.legislation.gov.uk\/ukpga\/2018\/12\/contents."},{"key":"9264_CR24","unstructured":"Commission Implementing Decision (EU) 2021\/914 of 4 June 2021 on standard contractual clauses for the transfer of personal data to third countries pursuant to Regulation (EU) 2016\/679 of the European Parliament and of the Council (text with EEA relevance). Official Journal of the European Union. 2021;64(L 199):31\u201361."},{"key":"9264_CR25","unstructured":"GOV.UK. EU adopts \u2018adequacy\u2019 decisions allowing data to continue flowing freely to the UK GOV.UK: Department for Digital, Culture, Media & Sport; 2021 [updated 28 June 2021. Press release ]. Available from: https:\/\/www.gov.uk\/government\/news\/eu-adopts-adequacy-decisions-allowing-data-to-continue-flowing-freely-to-the-uk."},{"key":"9264_CR26","volume":"59","author":"DP Harji","year":"2023","unstructured":"Harji DP, Koh C, McKigney N, Solomon MJ, Griffiths B, Evans M, et al. Development and validation of a patient reported outcome measure for health-related quality of life for locally recurrent rectal cancer: a multicentre, three-phase, mixed-methods, cohort study. eClin Med. 2023;59:101945.","journal-title":"eClin Med"},{"issue":"10","key":"9264_CR27","first-page":"5797","volume":"29","author":"MN Verkissen","year":"2021","unstructured":"Verkissen MN, De Vleminck A, Groenvold M, Jabbarian LJ, Bulli F, Cools W, et al. Functional impairment, symptom severity, and overall quality of life in patients with advanced lung or colorectal cancer in six European countries: baseline findings from the ACTION study. Support Care Cancer. 2021;29(10):5797\u2013810.","journal-title":"Support Care Cancer"},{"key":"9264_CR28","doi-asserted-by":"publisher","unstructured":"Diouf M, Chibaudel B, Filleron T. et al. Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study. Health Qual Life Outcomes. 2014;12:69. https:\/\/doi.org\/10.1186\/1477-7525-12-69.","DOI":"10.1186\/1477-7525-12-69"},{"key":"9264_CR29","unstructured":"POSTVenTT. * Newsletter August #09 is out! * Over 2700 patients enrolled! \u2026 [Twitter]2021. p. https:\/\/twitter.com\/postventt\/status\/1432531687884288006."},{"key":"9264_CR30","unstructured":"PITSTOP S. * Recruitment leaderboard update ! * Fantastic work by all sites \u2026. 29th January 2021 ed. [Twitter]2021.\u00a0https:\/\/twitter.com\/PITSTOP_Study\/status\/1355092256215195654."},{"key":"9264_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002670","author":"AK Kalpakidou","year":"2021","unstructured":"Kalpakidou AK, Todd C, Omar RZ, Keeley V, Griffiths J, Spencer K, et al. Study recruitment factors in advanced cancer: the prognosis in palliative care study II (PiPS2) - a multicentre, prospective, observational cohort project. BMJ Support Palliat Care. 2021. https:\/\/doi.org\/10.1136\/bmjspcare-2020-002670.","journal-title":"BMJ Support Palliat Care"},{"issue":"9","key":"9264_CR32","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.ejso.2019.04.005","volume":"45","author":"AE Vallance","year":"2019","unstructured":"Vallance AE, Harji D, Fearnhead NS. Making an IMPACT: a priority setting consultation exercise to improve outcomes in patients with locally advanced, recurrent and metastatic colorectal cancer. Eur J Surg Oncol. 2019;45(9):1567\u201374.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"9264_CR33","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1111\/codi.15670","volume":"23","author":"Q Denost","year":"2021","unstructured":"Denost Q, Frison E, Salut C, Sitta R, Rullier A, Harji D, et al. A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer \u2013 GRECCAR 15 trial protocol. Colorectal Dis. 2021;23(7):1909\u201318.","journal-title":"Colorectal Dis"},{"key":"9264_CR34","doi-asserted-by":"publisher","unstructured":"PelvEx Collaborative. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). BJS Open. 2021;5(3):zrab029. https:\/\/doi.org\/10.1093\/bjsopen\/zrab029. PMID: 34089596; PMCID: PMC8179511.","DOI":"10.1093\/bjsopen\/zrab029"},{"key":"9264_CR35","unstructured":"Research NIfHaC. Make a strong application www.nihr.ac.uk: NIHR; 2022 [Available from: https:\/\/www.nihr.ac.uk\/researchers\/apply-for-funding\/how-to-apply-for-project-funding\/make-a-strong-application.htm."},{"issue":"1","key":"9264_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13063-018-2535-5","volume":"19","author":"S Treweek","year":"2018","unstructured":"Treweek S, Bevan S, Bower P, Campbell M, Christie J, Clarke M, et al. Trial Forge Guidance 1: what is a Study Within A Trial (SWAT)? Trials. 2018;19(1):139.","journal-title":"Trials"},{"key":"9264_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1272-2","volume":"16","author":"P Dellson","year":"2016","unstructured":"Dellson P, Nilbert M, Carlsson C. Patient representatives\u2019 views on patient information in clinical cancer trials. BMC Health Serv Res. 2016;16:36.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"9264_CR38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1186\/s13063-020-04779-0","volume":"21","author":"HC Mattock","year":"2020","unstructured":"Mattock HC, Ryan R, O\u2019Farrelly C, Babalis D, Ramchandani PG. Does a video clip enhance recruitment into a parenting trial? Learnings from a study within a trial. Trials. 2020;21(1):856.","journal-title":"Trials"},{"issue":"7","key":"9264_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057508","volume":"12","author":"T Moe-Byrne","year":"2022","unstructured":"Moe-Byrne T, Knapp P, Perry D, Achten J, Spoors L, Appelbe D, et al. Does digital, multimedia information increase recruitment and retention in a children\u2019s wrist fracture treatment trial, and what do people think of it? A randomised controlled study within a trial (SWAT). BMJ Open. 2022;12(7):e057508.","journal-title":"BMJ Open"},{"issue":"1","key":"9264_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-000967","volume":"8","author":"KP Yip","year":"2021","unstructured":"Yip KP, Gompertz S, Snelson C, Willson J, Madathil S, Huq SS, et al. Increase in recruitment upon integration of trial into a clinical care pathway: an observational study. BMJ Open Respir Res. 2021;8(1):e000967.","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"9264_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7525-8-35","volume":"8","author":"CM Gundy","year":"2010","unstructured":"Gundy CM, Aaronson NK. Effects of mode of administration (MOA) on the measurement properties of the EORTC QLQ-C30: a randomized study. Health Qual Life Outcomes. 2010;8(1):35.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"9264_CR42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1524-4733.2008.00470.x","volume":"12","author":"SJ Coons","year":"2009","unstructured":"Coons SJ, Gwaltney CJ, Hays RD, Lundy JJ, Sloan JA, Revicki DA, et al. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO good research practices task force report. Value Health. 2009;12(4):419\u201329.","journal-title":"Value Health"},{"key":"9264_CR43","unstructured":"EORTC. Guidance on the implementation and management of EORTC quality of life instruments in electronic applications. www.qol.eortc.org: EORTC QLG; 2018."},{"issue":"1","key":"9264_CR44","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s13063-022-06333-6","volume":"23","author":"R Almeida-Magana","year":"2022","unstructured":"Almeida-Magana R, Maroof H, Grierson J, Clow R, Dinneen E, Al-Hammouri T, et al. E-consent\u2014a guide to maintain recruitment in clinical trials during the COVID-19 pandemic. Trials. 2022;23(1):388.","journal-title":"Trials"},{"key":"9264_CR45","first-page":"v77","volume":"29","author":"Z Maravic","year":"2018","unstructured":"Maravic Z, Trenevski JS, Bokros J, Casado AR, de Pedro CG, Otero MM, et al. Recruitment for a survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC): lessons from a European study. Ann Oncol. 2018;29:v77.","journal-title":"Ann Oncol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09264-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09264-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09264-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T02:40:09Z","timestamp":1780886409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-025-09264-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9264"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09264-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants recruited to the study provided informed written consent. Ethical approval was granted for all components of the study by the West of Scotland Research Ethics Committee 3, REC reference: 20\/WS\/0116.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Professor Galina Velikova: honoraria: Pfizer, Novartis, Eisai; advisory boards: consultancy fees from AstraZeneca, Roche, Novartis, Pfizer, Seagen, Eisai, Sanofi; institutional grant from Pfizer. No other interests to declare for all other authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"423"}}